Skip Navigation


BJA Advance Access originally published online on September 17, 2004
British Journal of Anaesthesia 2004 93(6):868-871; doi:10.1093/bja/aeh269
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
93/6/868    most recent
aeh269v1
Right arrow E-Letters: Submit a response to the article
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Stotz, M.
Right arrow Articles by Pargger, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stotz, M.
Right arrow Articles by Pargger, H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


© The Board of Management and Trustees of the British Journal of Anaesthesia 2004

CASE REPORT

Fulminant neuroleptic malignant syndrome after perioperative withdrawal of antiParkinsonian medication

M. Stotz1,*, D. Thümmler2, M. Schürch4, J.-C. Renggli2, A. Urwyler1 and H. Pargger3

1 Department of Anaesthesia, 2 Department of Surgery and 3 Division of Operative Critical Care, University of Basel/Kantonsspital, CH-4031 Basel, Switzerland and 4 Department of Anaesthesia, Kantonsspital Aarau, CH-5001 Aarau, Switzerland

* Corresponding author. Bloomsbury Institute of Intensive Care Medicine, University College London, Mortimer Street, London W1T 3AA, UK. E-mail: Stotzm{at}hotmail.com

Neuroleptic malignant syndrome is a rare complication when using neuroleptic drugs. We report the case of a patient with severe Parkinson's disease who developed neuroleptic malignant syndrome after withdrawal of his antiParkinsonian medication for elective coronary artery bypass grafting. Sodium dantrolene may be a therapeutic option in severe cases.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.